(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1512791

ファーマコビジランス市場、シェア、規模、動向、産業分析レポート：サービス別、製品ライフサイクル別、タイプ別、プロセスフロー別、治療領域別、最終用途別、地域別セグメント、2024年～2032年の予測

Pharmacovigilance Market Share, Size, Trends, Industry Analysis Report, By Service, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Use, By Region; Segment Forecast, 2024 - 2032

出版日
ページ情報
英文 117 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.06円
ファーマコビジランス市場、シェア、規模、動向、産業分析レポート：サービス別、製品ライフサイクル別、タイプ別、プロセスフロー別、治療領域別、最終用途別、地域別セグメント、2024年～2032年の予測
出版日: 2024年05月01日
発行: Polaris Market Research
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のファーマコビジランス市場規模は2032年までに137億5,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

市場の主な促進要因としては、薬剤摂取量の増加、新薬開発の頻度、薬物反応陰性や薬物毒性の価格上昇、ファーマコビジランスソリューションの契約傾向の拡大などが挙げられ、業界の成長を後押しすると期待されています。さらに、製薬部門の過剰な支出、薬物有害事象の発生率の上昇、薬物ミスが業界を前進させています。さらに、コロナウイルスのパンデミックは、ワクチンに対する緊急需要を生み出し、業界参加者にいくつかのチャンスを提供しています。

固定的な供給コストを変動費に変換し、オンデマンドで特徴的な専門知識に接触できるなどの利点があるため、予測期間中、外部委託契約セグメントが世界市場で主要シェアを占めると予想されます。

北米は、新薬導入に向けた業界プレイヤーの投資増加により、予測期間中、世界市場で主要シェアを占めると予想されます。さらに、米国やカナダのような国々では、先進的な医療制度の存在とともに、厳しい規制が業界の成長に有利な機会を生み出すと期待されています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のファーマコビジランス市場の洞察

  • ファーマコビジランス- 業界スナップショット
  • ファーマコビジランス市場力学
    • 促進要因と機会
      • 慢性疾患の蔓延
      • 医薬品開発への投資増加
    • 抑制要因と課題
      • データ管理に関する問題
  • PESTLE分析
  • ファーマコビジランス業界の動向
  • COVID-19の影響分析

第5章 世界のファーマコビジランス市場：サービスプロバイダー別

  • 主な調査結果
  • イントロダクション
  • 社内
  • 契約アウトソーシング

第6章 世界のファーマコビジランス市場：製品ライフサイクル別

  • 主な調査結果
  • イントロダクション
  • 前臨床
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第7章 世界のファーマコビジランス市場：治療領域別

  • 主な調査結果
  • イントロダクション
  • 腫瘍学
  • 神経学
  • 心臓病学
  • 呼吸器系
  • その他

第8章 世界のファーマコビジランス市場：プロセスフロー別

  • 主な調査結果
  • イントロダクション
  • ケースデータ管理
  • 信号検出
  • リスク管理システム

第9章 世界のファーマコビジランス市場：タイプ別

  • 主な調査結果
  • イントロダクション
  • 自発報告
  • ADR報告の強化
  • 対象事象自発報告
  • コホートイベントモニタリング
  • EHRマイニング

第10章 世界のファーマコビジランス市場：最終用途別

  • 主な調査結果
  • イントロダクション
  • 医薬品
  • バイオテクノロジー企業
  • 医療機器メーカー
  • その他

第11章 世界のファーマコビジランス市場：地域

  • 主な調査結果
  • イントロダクション
    • ファーマコビジランス市場の評価：地域別、2019-2032年
  • 北米
    • 北米：サービスプロバイダー別、2019年～2032年
    • 北米：プロセスフロー別、2019年～2032年
    • 北米：製品ライフサイクル別、2019～2032年
    • 北米：タイプ別、2019-2032年
    • 北米：治療領域別、2019年～2032年
    • 北米：最終用途別、2019年～2032年
    • 米国
    • カナダ
  • 欧州
    • 欧州：サービスプロバイダー別、2019-2032年
    • 欧州：プロセスフロー別、2019-2032年
    • 欧州：製品ライフサイクル別、2019-2032
    • 欧州：タイプ別、2019-2032
    • 欧州：治療領域別、2019年～2032年
    • 欧州：最終用途別、2019年～2032年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
  • アジア太平洋地域
    • アジア太平洋地域：サービスプロバイダー別、2019-2032年
    • アジア太平洋地域：プロセスフロー別、2019年～2032年
    • アジア太平洋地域：製品ライフサイクル別、2019年～2032年
    • アジア太平洋地域：タイプ別、2019-2032
    • アジア太平洋地域：治療領域別、2019年～2032年
    • アジア太平洋地域：最終用途別、2019年～2032年
    • 中国
    • インド
    • 日本
    • マレーシア
    • インドネシア
    • 韓国
  • 中東・アフリカ
    • 中東・アフリカ：サービスプロバイダー別、2019-2032年
    • 中東・アフリカ：プロセスフロー別、2019-2032年
    • 中東・アフリカ：製品ライフサイクル別、2019-2032
    • 中東・アフリカ：タイプ別、2019年～2032年
    • 中東・アフリカ：治療領域別、2019年～2032年
    • 中東・アフリカ：最終用途別、2019年～2032年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：サービスプロバイダー別、2019年～2032年
    • ラテンアメリカ：プロセスフロー別、2019-2032年
    • ラテンアメリカ：製品ライフサイクル別、2019年～2032年
    • ラテンアメリカ：タイプ別、2019-2032年
    • ラテンアメリカ：治療領域別、2019年～2032年
    • ラテンアメリカ：最終用途別、2019年～2032年
    • メキシコ
    • ブラジル
    • アルゼンチン

第12章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第13章 企業プロファイル

  • Accenture
  • ArisGlobal
  • BioClinica, Inc
  • Capgemini
  • Clinquest Group B.V.（Linical Americas）
  • Cognizant
  • FMD K&L
  • IBM Corporation
  • ICON Plc.
  • IQVIA
  • ITClinical
  • Laboratory Corporation of America Holdings
  • Linical Accelovance
  • PAREXEL International Corporation
  • TAKE Solutions
  • United BioSource Corporation
  • Wipro Limited
図表

List of Tables

  • Table 1 Global Pharmacovigilance Market, by Service Provider, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Pharmacovigilance Market, by Process Flow, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Pharmacovigilance Market, by Product Life Cycle, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Pharmacovigilance Market, by Type, by Region, 2019-2032 (USD Billion)
  • Table 5 Global Pharmacovigilance Market, by Therapeutic Area, by Region, 2019-2032 (USD Billion)
  • Table 6 Global Pharmacovigilance Market, by End-Use, by Region, 2019-2032 (USD Billion)
目次
Product Code: PM2355

The global pharmacovigilance market size is expected to reach USD 13.75 Billion by 2032 according to a new study by Polaris Market Research. The report "Pharmacovigilance Market Share, Size, Trends, Industry Analysis Report, By Service, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Use, By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The primary drivers of the market include rising medication intake novel drug development frequencies, rising prices of negative drug responses and drug toxicities, as well as an expanding tendency of contracting pharmacovigilance solutions is expected to boost the industry growth. Moreover, the pharmaceutical sector's excessive expenditure, rising incidence of adverse drug events, and drug mistakes are propelling the industry forward. Furthermore, the coronavirus pandemic has produced an emergency demand for a vaccine that has offered several chances for industry participants.

The contract outsources segment is expected to hold the major shares in the global market during the forecast period due to its benefits such as transforming fixed supply costs into variables, refining on-demand contact to distinctive expertise along with other benefits.

North America is expected to hold the major share in the global market over the forecast period due to increasing investment by the industry players in introducing novel drugs. Moreover, stringent regulations along with the presence of advanced healthcare systems in countries like the U.S. and Canada are expected to create lucrative opportunities for industry growth.

Some of the major players operating in the global market are ArisGlobal, Accenture, BioClinica, Inc., United BioSource Corporation, Clinquest Group B.V. (Linical Americas), Cognizant, Capgemini, FMD K&L, IBM Corporation, IQVIA, ICON Plc., ITClinical, Linical Accelovance, PAREXEL International Corporation, Laboratory Corporation of America Holdings, TAKE Solutions, and Wipro Limited.

Polaris Market Research has segmented the pharmacovigilance market report on the basis of service provider, product life cycle, type, process flow, therapeutic area, end-use, and region:

Pharmacovigilance, Service Provider Outlook (Revenue - USD Billion, 2019-2032)

  • In-house
  • Contract Outsourcing

Pharmacovigilance, Product Life Cycle Outlook (Revenue - USD Billion, 2019-2032)

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Pharmacovigilance, Type Outlook (Revenue - USD Billion, 2019-2032)

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Pharmacovigilance, Process Flow Outlook (Revenue - USD Billion, 2019-2032)

  • Case Data Management
  • Case Logging
  • Case Data Analysis
  • Medical Reviewing & Reporting
  • Signal Detection
  • Adverse Event Logging
  • Adverse Event Analysis
  • Adverse Event Review & Reporting
  • Risk Management System
  • Risk Evaluation System
  • Risk Mitigation System

Pharmacovigilance, Therapeutic Area Outlook (Revenue - USD Billion, 2019-2032)

  • Oncology
  • Neurology
  • Cardiology
  • Respiratory Systems
  • Others

Pharmacovigilance, End-Use Outlook (Revenue - USD Billion, 2019-2032)

  • Pharmaceuticals
  • Biotechnology Companies
  • Medical Device Manufacturers
  • Others

Pharmacovigilance, Regional Outlook (Revenue - USD Billion, 2019-2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • Italy
  • France
  • Netherlands
  • Russia
  • Spain
  • Asia Pacific
  • China
  • Japan
  • India
  • Indonesia
  • Malaysia
  • South Korea
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Middle East & Africa
  • Israel
  • Saudi Arabia
  • South Africa
  • UAE

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Pharmacovigilance Market Insights

  • 4.1. Pharmacovigilance - Industry Snapshot
  • 4.2. Pharmacovigilance Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of chronic disease
      • 4.2.1.2. Increasing investment in drug development
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Issues related to data management
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Pharmacovigilance Industry Trends
  • 4.6. COVID-19 Impact Analysis

5. Global Pharmacovigilance Market, by Service Provider

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
  • 5.3. In-house
    • 5.3.1. Global Pharmacovigilance Market, by In-house, by Region, 2019-2032 (USD Billion)
  • 5.4. Contract Outsourcing
    • 5.4.1. Global Pharmacovigilance Market, by Contract Outsourcing, by Region, 2019-2032 (USD Billion)

6. Global Pharmacovigilance Market, by Product Life Cycle

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
  • 6.3. Pre-clinical
    • 6.3.1. Global Pharmacovigilance Market, by Pre-clinical, by Region, 2019-2032 (USD Billion)
  • 6.4. Phase I
    • 6.4.1. Global Pharmacovigilance Market, by Phase I, by Region, 2019-2032 (USD Billion)
  • 6.5. Phase II
    • 6.5.1. Global Pharmacovigilance Market, by Phase II, by Region, 2019-2032 (USD Billion)
  • 6.6. Phase III
    • 6.6.1. Global Pharmacovigilance Market, by Phase III, by Region, 2019-2032 (USD Billion)
  • 6.7. Phase IV
    • 6.7.1. Global Pharmacovigilance Market, by Phase IV, by Region, 2019-2032 (USD Billion)

7. Global Pharmacovigilance Market, by Therapeutic Area

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 7.3. Oncology
    • 7.3.1. Global Pharmacovigilance Market, by Oncology, by Region, 2019-2032 (USD Billion)
  • 7.4. Neurology
    • 7.4.1. Global Pharmacovigilance Market, by Neurology, by Region, 2019-2032 (USD Billion)
  • 7.5. Cardiology
    • 7.5.1. Global Pharmacovigilance Market, by Cardiology, by Region, 2019-2032 (USD Billion)
  • 7.6. Respiratory Systems
    • 7.6.1. Global Pharmacovigilance Market, by Respiratory Systems, by Region, 2019-2032 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Other Pharmacovigilance Market, by Region, 2019-2032 (USD Billion)

8. Global Pharmacovigilance Market, by Process Flow

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
  • 8.3. Case Data Management
    • 8.3.1. Global Pharmacovigilance Market, by Case Data Management, by Region, 2019-2032 (USD Billion)
    • 8.3.2. Case Logging
      • 8.3.2.1. Global Pharmacovigilance Market, by Case Logging, by Region, 2019-2032 (USD Billion)
    • 8.3.3. Case Data Analysis
      • 8.3.3.1. Global Pharmacovigilance Market, by Case Data Analysis, by Region, 2019-2032 (USD Billion)
    • 8.3.4. Medical Reviewing & Reporting
      • 8.3.4.1. Global Pharmacovigilance Market, by Medical Reviewing & Reporting, by Region, 2019-2032 (USD Billion)
  • 8.4. Signal Detection
    • 8.4.1. Global Pharmacovigilance Market, by Signal Detection, by Region, 2019-2032 (USD Billion)
    • 8.4.2. Adverse Event Logging
      • 8.4.2.1. Global Pharmacovigilance Market, by Adverse Event Logging, by Region, 2019-2032 (USD Billion)
    • 8.4.3. Adverse Event Analysis
      • 8.4.3.1. Global Pharmacovigilance Market, by Adverse Event Analysis, by Region, 2019-2032 (USD Billion)
    • 8.4.4. Adverse Event Review & Reporting
      • 8.4.4.1. Global Pharmacovigilance Market, by Adverse Event Review & Reporting, by Region, 2019-2032 (USD Billion)
  • 8.5. Risk Management System
    • 8.5.1. Global Pharmacovigilance Market, by Risk Management System, by Region, 2019-2032 (USD Billion)
    • 8.5.2. Risk Evaluation System
      • 8.5.2.1. Global Pharmacovigilance Market, by Risk Evaluation System, by Region, 2019-2032 (USD Billion)
    • 8.5.3. Risk Mitigation System
      • 8.5.3.1. Global Pharmacovigilance Market, by Risk Mitigation System, by Region, 2019-2032 (USD Billion)

9. Global Pharmacovigilance Market, by Type

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 9.3. Spontaneous Reporting
    • 9.3.1. Global Pharmacovigilance Market, by Spontaneous Reporting, by Region, 2019-2032 (USD Billion)
  • 9.4. Intensified ADR Reporting
    • 9.4.1. Global Pharmacovigilance Market, by Intensified ADR Reporting, by Region, 2019-2032 (USD Billion)
  • 9.5. Targeted Spontaneous Reporting
    • 9.5.1. Global Pharmacovigilance Market, by Targeted Spontaneous Reporting, by Region, 2019-2032 (USD Billion)
  • 9.6. Cohort Event Monitoring
    • 9.6.1. Global Pharmacovigilance Market, by Cohort Event Monitoring, by Region, 2019-2032 (USD Billion)
  • 9.7. EHR Mining
    • 9.7.1. Global Pharmacovigilance Market, by EHR Mining, by Region, 2019-2032 (USD Billion)

10. Global Pharmacovigilance Market, by End-Use

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. Global Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 10.3. Pharmaceuticals
    • 10.3.1. Global Pharmacovigilance Market, by Pharmaceuticals, by Region, 2019-2032 (USD Billion)
  • 10.4. Biotechnology Companies
    • 10.4.1. Global Pharmacovigilance Market, by Biotechnology Companies, by Region, 2019-2032 (USD Billion)
  • 10.5. Medical Device Manufacturers
    • 10.5.1. Global Pharmacovigilance Market, by Medical Device Manufacturers, by Region, 2019-2032 (USD Billion)
  • 10.6. Others
    • 10.6.1. Global Other End-Uses Pharmacovigilance Market, by Region, 2019-2032 (USD Billion)

11. Global Pharmacovigilance Market, by Geography

  • 11.1. Key findings
  • 11.2. Introduction
    • 11.2.1. Pharmacovigilance Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 11.3. Pharmacovigilance Market - North America
    • 11.3.1. North America: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.3.2. North America: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.3.3. North America: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.3.4. North America: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.3.5. North America: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.3.6. North America: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.3.7. Pharmacovigilance Market - U.S.
      • 11.3.7.1. U.S.: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.3.7.2. U.S.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.3.7.3. U.S.: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.3.7.4. U.S.: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.3.7.5. U.S.: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.3.7.6. U.S.: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.3.8. Pharmacovigilance Market - Canada
      • 11.3.8.1. Canada: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.3.8.2. Canada.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.3.8.3. Canada: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.3.8.4. Canada: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.3.8.5. Canada: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.3.8.6. Canada: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4. Pharmacovigilance Market - Europe
    • 11.4.1. Europe: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.2. Europe.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.3. Europe: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.4. Europe: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.5. Europe: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.6. Europe: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.7. Pharmacovigilance Market - UK
      • 11.4.7.1. UK: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.7.2. UK.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.7.3. UK: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.7.4. UK: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.7.5. UK: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.7.6. UK: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.8. Pharmacovigilance Market - France
      • 11.4.8.1. France: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.8.2. France.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.8.3. France: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.8.4. France: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.8.5. France: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.8.6. France: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.9. Pharmacovigilance Market - Germany
      • 11.4.9.1. Germany: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.9.2. Germany.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.9.3. Germany: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.9.4. Germany: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.9.5. Germany: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.9.6. Germany: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.10. Pharmacovigilance Market - Italy
      • 11.4.10.1. Italy: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.10.2. Italy.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.10.3. Italy: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.10.4. Italy: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.10.5. Italy: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.10.6. Italy: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.11. Pharmacovigilance Market - Spain
      • 11.4.11.1. Spain: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.11.2. Spain.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.11.3. Spain: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.11.4. Spain: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.11.5. Spain: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.11.6. Spain: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.12. Pharmacovigilance Market - Netherlands
      • 11.4.12.1. Netherlands: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.12.2. Netherlands.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.12.3. Netherlands: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.12.4. Netherlands: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.12.5. Netherlands: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.12.6. Netherlands: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.13. Pharmacovigilance Market - Russia
      • 11.4.13.1. Russia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.13.2. Russia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.13.3. Russia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.13.4. Russia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.13.5. Russia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.13.6. Russia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.5. Pharmacovigilance Market - Asia Pacific
    • 11.5.1. Asia Pacific: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.5.2. Asia Pacific.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.5.3. Asia Pacific: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.5.4. Asia Pacific: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.5.5. Asia Pacific: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.5.6. Asia Pacific: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.7. Pharmacovigilance Market - China
      • 11.5.7.1. China: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.7.2. China.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.7.3. China: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.7.4. China: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.7.5. China: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.7.6. China: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.8. Pharmacovigilance Market - India
      • 11.5.8.1. India: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.8.2. India.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.8.3. India: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.8.4. India: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.8.5. India: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.8.6. India: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.9. Pharmacovigilance Market - Japan
      • 11.5.9.1. Japan: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.9.2. Japan.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.9.3. Japan: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.9.4. Japan: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.9.5. Japan: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.9.6. Japan: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.10. Pharmacovigilance Market - Malaysia
      • 11.5.10.1. Malaysia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.10.2. Malaysia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.10.3. Malaysia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.10.4. Malaysia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.10.5. Malaysia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.10.6. Malaysia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.11. Pharmacovigilance Market - Indonesia
      • 11.5.11.1. Indonesia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.11.2. Indonesia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.11.3. Indonesia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.11.4. Indonesia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.11.5. Indonesia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.11.6. Indonesia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.12. Pharmacovigilance Market - South Korea
      • 11.5.12.1. South Korea: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.12.2. South Korea.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.12.3. South Korea: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.12.4. South Korea: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.12.5. South Korea: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.12.6. South Korea: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.6. Pharmacovigilance Market - Middle East & Africa
    • 11.6.1. Middle East & Africa: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.6.2. Middle East & Africa: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.6.3. Middle East & Africa: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.6.4. Middle East & Africa: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.6.5. Middle East & Africa: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.6.6. Middle East & Africa: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.7. Pharmacovigilance Market - Saudi Arabia
      • 11.6.7.1. Saudi Arabia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.7.2. Saudi Arabia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.7.3. Saudi Arabia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.7.4. Saudi Arabia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.7.5. Saudi Arabia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.7.6. Saudi Arabia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.8. Pharmacovigilance Market - UAE
      • 11.6.8.1. UAE: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.8.2. UAE.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.8.3. UAE: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.8.4. UAE: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.8.5. UAE: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.8.6. UAE: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.9. Pharmacovigilance Market - Israel
      • 11.6.9.1. Israel: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.9.2. Israel.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.9.3. Israel: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.9.4. Israel: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.9.5. Israel: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.9.6. Israel: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.10. Pharmacovigilance Market - South Africa
      • 11.6.10.1. South Africa: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.10.2. South Africa.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.10.3. South Africa: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.10.4. South Africa: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.10.5. South Africa: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.10.6. South Africa: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.7. Pharmacovigilance Market - Latin America
    • 11.7.1. Latin America: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.7.2. Latin America.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.7.3. Latin America: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.7.4. Latin America: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.7.5. Latin America: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.7.6. Latin America: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.7. Pharmacovigilance Market - Mexico
      • 11.7.7.1. Mexico: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.7.2. Mexico.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.7.3. Mexico: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.7.4. Mexico: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.7.5. Mexico: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.7.6. Mexico: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.8. Pharmacovigilance Market - Brazil
      • 11.7.8.1. Brazil: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.8.2. Brazil.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.8.3. Brazil: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.8.4. Brazil: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.8.5. Brazil: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.8.6. Brazil: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.9. Pharmacovigilance Market - Argentina
      • 11.7.9.1. Argentina: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.9.2. Argentina.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.9.3. Argentina: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.9.4. Argentina: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.9.5. Argentina: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.9.6. Argentina: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)

12. Competitive Landscape

  • 12.1. Expansion and Acquisition Analysis
    • 12.1.1. Expansion
    • 12.1.2. Acquisitions
  • 12.2. Partnerships/Collaborations/Agreements/Exhibitions

13. Company Profiles

  • 13.1. Accenture
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Benchmarking
    • 13.1.4. Recent Development
  • 13.2. ArisGlobal
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Benchmarking
    • 13.2.4. Recent Development
  • 13.3. BioClinica, Inc
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Benchmarking
    • 13.3.4. Recent Development
  • 13.4. Capgemini
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Benchmarking
    • 13.4.4. Recent Development
  • 13.5. Clinquest Group B.V. (Linical Americas)
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Benchmarking
    • 13.5.4. Recent Development
  • 13.6. Cognizant
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Benchmarking
    • 13.6.4. Recent Development
  • 13.7. FMD K&L
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Benchmarking
    • 13.7.4. Recent Development
  • 13.8. IBM Corporation
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Benchmarking
    • 13.8.4. Recent Development
  • 13.9. ICON Plc.
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Benchmarking
    • 13.9.4. Recent Development
  • 13.10. IQVIA
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Benchmarking
    • 13.10.4. Recent Development
  • 13.11. ITClinical
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Benchmarking
    • 13.11.4. Recent Development
  • 13.12. Laboratory Corporation of America Holdings
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Benchmarking
    • 13.12.4. Recent Development
  • 13.13. Linical Accelovance
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Benchmarking
    • 13.13.4. Recent Development
  • 13.14. PAREXEL International Corporation
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Benchmarking
    • 13.14.4. Recent Development
  • 13.15. TAKE Solutions
    • 13.15.1. Company Overview
    • 13.15.2. Financial Performance
    • 13.15.3. Product Benchmarking
    • 13.15.4. Recent Development
  • 13.16. United BioSource Corporation
    • 13.16.1. Company Overview
    • 13.16.2. Financial Performance
    • 13.16.3. Product Benchmarking
    • 13.16.4. Recent Development
  • 13.17. Wipro Limited
    • 13.17.1. Company Overview
    • 13.17.2. Financial Performance
    • 13.17.3. Product Benchmarking
    • 13.17.4. Recent Development